News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium.


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-001048,00.asp

Posted on: 06/08/2004

Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium.

Meeting: 2004 ASCO Annual Meeting

Category: Central Nervous System Tumors

SubCategory: CNS Tumors

Abstract No: 1541

Author(s): B. Neyns, E. Everaert, E. Joosens, T. Strauven, F. Branle, J. Menten; AZ-VUB, Brussels, Belgium; UZ KUL, Leuven, Belgium; AZ Middelheim, Antwerpen, Belgium; AZ Sint-Augustinus, Wilrijk, Belgium; Hôpital Erasme ULB, Brussels, Belgium

Abstract: Background: Temozolomide (TMZ) is an oral alkylating agent that has demonstrated objective activity and an acceptable toxicity profile for the treatment of recurrent high-grade gliomas in phase II trials. Only limited information is available on the activity and toxicity of TMZ when prescribed outside a clinical trial. Methods: We conducted a retrospective study to evaluate the activity and safety of TMZ that was prescribed for the treatment of recurrent glioma in the context of a compassionate use program in Belgium. Data were obtained on 117 adult patients (from 5 hospitals) who received TMZ as first or second line chemotherapy. The recommended starting dose of TMZ was 200 mg/m2 x5d q28d for chemonaïve patients and 150 mg/m2 x5d q28d for pretreated patients.

Results: Toxicity was generally mild although grade 3/4 toxicity was observed in 22 % of patients. Thrombocytopenia was the most frequent encountered toxicity (grade 3/4 in 17% of patients) and its occurrence was correlated with a starting dose of 200 mg/m²/d. The overall RR (CR + PR) was 29% and 34 % of patients achieved a SD. The median PFS was 104 days (95% CI 85-123) and the median OS was 215 days (95% CI 161-269). In multivariate analysis a “deep localization” of the glioma (as opposed to a cortico-subcortical localization) and the preceding history of a low-grade glioma were identified as independent prognostic variables with regard to TTP & OS. Administration of TMZ as first line chemotherapy was an independent prognostic variable for TTP only. Absence of disease progression at the end of TMZ cycle 3 was significantly correlated with a superior overall survival (landmark analysis, P<0.0001). Conclusions: This retrospective study indicates that the reported activity and toxicity profile of TMZ for the treatment of patients with recurrent glioma is reproducible outside the setting of a prospective clinical trial.




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740